Wuhan Neurophth Biotechnology Limited Company
纽福斯
Wuhan Neurophth Biotechnology Limited Company
Biotech/Healthcare
The company has successfully designed a gene therapy candidate for Leber hereditary optic neuropathy (LHON). To date, it has completed clinical trials involving 152 LHON patients, including seven patients in Argentina.
Latest round: Series C Extension (2023)
Source: ChinaBulls — chinabulls.com
Last updated 2023-08-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.